Bank of Montreal Can Has $11.46 Million Stock Position in Sanofi (NASDAQ:SNY)

Bank of Montreal Can lessened its holdings in Sanofi (NASDAQ:SNY - Free Report) by 7.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 237,576 shares of the company's stock after selling 18,862 shares during the period. Bank of Montreal Can's holdings in Sanofi were worth $11,458,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. State Street Corp lifted its holdings in shares of Sanofi by 0.5% in the third quarter. State Street Corp now owns 56,734 shares of the company's stock valued at $3,270,000 after purchasing an additional 264 shares in the last quarter. Barclays PLC raised its position in Sanofi by 107.5% in the 3rd quarter. Barclays PLC now owns 639,772 shares of the company's stock valued at $36,869,000 after buying an additional 331,445 shares during the last quarter. Geode Capital Management LLC lifted its stake in Sanofi by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock valued at $14,681,000 after acquiring an additional 16,780 shares in the last quarter. Coldstream Capital Management Inc. grew its stake in shares of Sanofi by 16.6% in the 3rd quarter. Coldstream Capital Management Inc. now owns 6,081 shares of the company's stock worth $350,000 after acquiring an additional 866 shares in the last quarter. Finally, Sunbelt Securities Inc. raised its holdings in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock valued at $43,000 after purchasing an additional 313 shares during the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

Shares of SNY stock opened at $51.50 on Friday. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The firm's 50-day simple moving average is $54.97 and its two-hundred day simple moving average is $52.38. The firm has a market cap of $130.10 billion, a price-to-earnings ratio of 20.68, a P/E/G ratio of 1.01 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Remove Ads

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, equities analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SNY. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group started coverage on Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi presently has an average rating of "Moderate Buy" and an average target price of $62.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.